Leukaemia: Drugs

Department of Health written question – answered on 3rd November 2017.

Alert me about debates like this

Photo of Alec Shelbrooke Alec Shelbrooke Conservative, Elmet and Rothwell

To ask the Secretary of State for Health, for what reasons ibrutinib is not prescribed on the NHS as a treatment for chronic lymphocytic leukaemia.

Photo of Steve Brine Steve Brine The Parliamentary Under-Secretary of State for Health

The National Institute for Health and Care Excellence (NICE) published technology appraisal guidance in January 2017 that recommends ibrutinib for the treatment of chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation. Ibrutinib is routinely available to National Health Service patients for these indications in line with NICE’s recommendations if a patient’s doctor considers it to be the most appropriate treatment option.

NICE has not been able to make a recommendation on the use of ibrutinib for use in the treatment of other patients with chronic lymphocytic leukaemia because no evidence submission was received from the product’s manufacturer. Ibrutinib is not therefore routinely commissioned for NHS patients for these other indications. NICE will review this decision if the company decides to make an evidence submission.

Does this answer the above question?

Yes1 person thinks so

No0 people think not

Would you like to ask a question like this yourself? Use our Freedom of Information site.